123 related articles for article (PubMed ID: 8260445)
1. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.
Dixon L; Thaker G; Conley R; Ross D; Cascella N; Tamminga C
Schizophr Res; 1993 Oct; 10(3):267-71. PubMed ID: 8260445
[TBL] [Abstract][Full Text] [Related]
2. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
Singh H; Hunt JI; Vitiello B; Simpson GM
J Clin Psychiatry; 1990 Aug; 51(8):319-21. PubMed ID: 1974249
[TBL] [Abstract][Full Text] [Related]
3. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures.
Gardos G; Cole JO; Rapkin RM; LaBrie RA; Baquelod E; Moore P; Sovner R; Doyle J
Arch Gen Psychiatry; 1984 Nov; 41(11):1030-5. PubMed ID: 6149737
[TBL] [Abstract][Full Text] [Related]
4. Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients.
Steinhauer SR; van Kammen DP; Colbert K; Peters JL; Zubin J
Psychiatry Res; 1992 Sep; 43(3):287-98. PubMed ID: 1438625
[TBL] [Abstract][Full Text] [Related]
5. Clinical predictors of relapse following neuroleptic withdrawal.
Buchanan RW; Kirkpatrick B; Summerfelt A; Hanlon TE; Levine J; Carpenter WT
Biol Psychiatry; 1992 Jul; 32(1):72-8. PubMed ID: 1356490
[TBL] [Abstract][Full Text] [Related]
6. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
Goff DC; Posever T; Herz L; Simmons J; Kletti N; Lapierre K; Wilner KD; Law CG; Ko GN
J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
[TBL] [Abstract][Full Text] [Related]
7. Treatment of late-life schizophrenia with neuroleptics.
Jeste DV; Lacro JP; Gilbert PL; Kline J; Kline N
Schizophr Bull; 1993; 19(4):817-30. PubMed ID: 7905663
[TBL] [Abstract][Full Text] [Related]
8. The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia.
Klieser E; Strauss WH; Lemmer W
Acta Psychiatr Scand Suppl; 1994; 380():68-73. PubMed ID: 8048341
[TBL] [Abstract][Full Text] [Related]
9. Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses.
Leblanc G; Cormier H; Gagné MA; Vaillancourt S
Can J Psychiatry; 1994 May; 39(4):223-9. PubMed ID: 7913872
[TBL] [Abstract][Full Text] [Related]
10. Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study.
Alphs LD; Lee HS
J Clin Psychiatry; 1991 Aug; 52(8):346-8. PubMed ID: 1869497
[TBL] [Abstract][Full Text] [Related]
11. Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.
Apud JA; Egan MF; Wyatt RJ
Schizophr Res; 2003 Sep; 63(1-2):151-60. PubMed ID: 12892869
[TBL] [Abstract][Full Text] [Related]
12. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia.
Glazer WM; Hafez H
Schizophr Res; 1990; 3(5-6):315-20. PubMed ID: 1980827
[TBL] [Abstract][Full Text] [Related]
13. [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():36-40. PubMed ID: 1683338
[TBL] [Abstract][Full Text] [Related]
14. Diurnal variation in tardive dyskinesia.
Hyde TM; Egan MF; Brown RJ; Weinberger DR; Kleinman JE
Psychiatry Res; 1995 Jan; 56(1):53-7. PubMed ID: 7792342
[TBL] [Abstract][Full Text] [Related]
15. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
16. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
17. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication.
Glazer WM; Morgenstern H; Schooler N; Berkman CS; Moore DC
Br J Psychiatry; 1990 Oct; 157():585-92. PubMed ID: 1983390
[TBL] [Abstract][Full Text] [Related]
18. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
[TBL] [Abstract][Full Text] [Related]
19. Expected incidence of tardive dyskinesia associated with atypical antipsychotics.
Glazer WM
J Clin Psychiatry; 2000; 61 Suppl 4():21-6. PubMed ID: 10739327
[TBL] [Abstract][Full Text] [Related]
20. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
